Elsevier

Annals of Oncology

Volume 31, Supplement 4, September 2020, Pages S559-S560
Annals of Oncology

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

https://doi.org/10.1016/j.annonc.2020.08.783Get rights and content
Under an Elsevier user license
open archive

Cited by (0)